Equities

Mankind Pharma Ltd

MANKIND:NSI

Mankind Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)2,554.00
  • Today's Change-6.10 / -0.24%
  • Shares traded116.79k
  • 1 Year change+32.15%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 10:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy5
Outperform5
Hold3
Sell1
Strong Sell0

Share price forecast in INR

The 14 analysts offering 12 month price targets for Mankind Pharma Ltd have a median target of 2,852.50, with a high estimate of 3,300.00 and a low estimate of 2,040.00. The median estimate represents a 11.42% increase from the last price of 2,560.10.
High28.9%3,300.00
Med11.4%2,852.50
Low-20.3%2,040.00

Dividends

Historical dividend information is not available for Mankind Pharma Ltd.
Div growth (TTM)--
More ▼

Earnings history & estimates in INR

On Nov 05, 2024, Mankind Pharma Ltd reported 2nd quarter 2025 earnings of 16.28 per share. This result exceeded the 14.55 consensus of the 2 analysts covering the company and exceeded last year's 2nd quarter results by 30.34%.
The next earnings announcement is expected on Feb 03, 2025.
Average growth rate+7.50%
Mankind Pharma Ltd reported annual 2024 earnings of 47.68 per share on May 15, 2024.
Average growth rate+49.00%
More ▼

Revenue history & estimates in INR

Mankind Pharma Ltd had 2nd quarter 2025 revenues of 30.77bn. This bettered the 30.45bn consensus of the 6 analysts covering the company. This was 13.60% above the prior year's 2nd quarter results.
Average growth rate+3.69%
Mankind Pharma Ltd had revenues for the full year 2024 of 103.35bn. This was 18.12% above the prior year's results.
Average growth rate+18.12%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.